S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
International Paper's 5% Yield Offers Big Value
Warren Buffett's company dumps another 5 million shares of printer maker HP
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
This Is One of the Top-Rated and Most-Upgraded Stocks
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
International Paper's 5% Yield Offers Big Value
Warren Buffett's company dumps another 5 million shares of printer maker HP
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
This Is One of the Top-Rated and Most-Upgraded Stocks
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
International Paper's 5% Yield Offers Big Value
Warren Buffett's company dumps another 5 million shares of printer maker HP
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
This Is One of the Top-Rated and Most-Upgraded Stocks
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
International Paper's 5% Yield Offers Big Value
Warren Buffett's company dumps another 5 million shares of printer maker HP
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
This Is One of the Top-Rated and Most-Upgraded Stocks
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
NASDAQ:CRTX

Cortexyme (CRTX) Stock Forecast, Price & News

$1.17
+0.10 (+9.35%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.03
▼
$1.20
50-Day Range
$1.07
▼
$1.95
52-Week Range
$1.78
▼
$40.66
Volume
177,909 shs
Average Volume
620,672 shs
Market Capitalization
$35.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media

CRTX stock logo

About Cortexyme (NASDAQ:CRTX) Stock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX Price History

CRTX Stock News Headlines

August 1, 2022 | marketscreener.com
Cortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.com
July 27, 2022 | marketscreener.com
Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.com
October 4, 2023 | Goldco (Ad)
Ben Stein FREE Report: How Americans Are RUINING Retirement
There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!
July 27, 2022 | businesswire.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business Wire
July 27, 2022 | businesswire.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business Wire
July 27, 2022 | marketscreener.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.com
July 27, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo Finance
July 27, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
October 4, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
July 27, 2022 | finance.yahoo.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
July 22, 2022 | streetinsider.com
Cortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.com
June 26, 2022 | gurufocus.com
Bragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.com
June 21, 2022 | benzinga.com
Cortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - Benzinga
June 21, 2022 | nasdaq.com
Cortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - Nasdaq
June 21, 2022 | finance.yahoo.com
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
June 13, 2022 | businesswire.com
Cortexyme Appoints June Bray to its Board of Directors - Business Wire
June 13, 2022 | finance.yahoo.com
Cortexyme Appoints June Bray to its Board of Directors - Yahoo Finance
June 13, 2022 | finance.yahoo.com
Cortexyme Appoints June Bray to its Board of Directors
June 11, 2022 | marketscreener.com
Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.com
June 10, 2022 | marketscreener.com
Cortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
May 22, 2022 | businesswire.com
Cortexyme Successfully Completes Acquisition of Novosteo - Business Wire
May 20, 2022 | nasdaq.com
This Is the Worst Type of Credit Card for Most Consumers - Nasdaq
May 20, 2022 | finance.yahoo.com
PPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo Finance
May 20, 2022 | marketscreener.com
Cortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.com
May 20, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Acquisition of Novosteo - Yahoo Finance
May 20, 2022 | finance.yahoo.com
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
May 13, 2022 | nasdaq.com
Pre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - Nasdaq
See More Headlines
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Company Calendar

Last Earnings
8/09/2021
Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
CIK
1145404
Web
www.cortexyme.com
Phone
(650) 910-5717
Fax
N/A
Employees
55
Year Founded
2012

Profitability

EPS (Most Recent Fiscal Year)
($2.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,940,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-70.96%
Return on Assets
-63.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.92
Quick Ratio
9.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
30,151,000
Free Float
21,739,000
Market Cap
$35.28 million
Optionable
Not Optionable
Beta
1.40

Social Links

Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Leslie J. Holsinger Ph.D. (Age 57)
    Exec. VP of R&D
    Comp: $603.85k
  • Dr. Dirk Thye M.D. (Age 52)
    CEO & Director
  • Mr. Ted Monohon (Age 56)
    VP of Fin., Principal Financial Officer & Chief Accounting Officer
  • Mr. Brendan Hannah M.B.A.
    Chief Bus. Officer
  • Dr. Karen L. Smith L.L.M (Age 54)
    L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer

Key Competitors

View All Competitors













CRTX Stock - Frequently Asked Questions

How have CRTX shares performed in 2023?

Cortexyme's stock was trading at $0.6374 at the beginning of 2023. Since then, CRTX stock has increased by 83.6% and is now trading at $1.17.
View the best growth stocks for 2023 here.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) issued its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

When did Cortexyme IPO?

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $1.17.

How much money does Cortexyme make?

Cortexyme (NASDAQ:CRTX) has a market capitalization of $35.28 million. The biopharmaceutical company earns $-89,940,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cortexyme.com. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at ir@cortexyme.com.

This page (NASDAQ:CRTX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -